Shahbaz et al. find that female long COVID patients with ME/CFS exhibit heightened inflammation, altered hematopoiesis, disrupted hormone levels, and neuroinflammatory gene signatures. In parallel, our study identifies sex-specific immune and hormonal biomarkers that correlate with clinical symptoms, supporting the need for tailored therapeutic strategies, including consideration of hormone replacement therapy.

Presenter: Dr Daniel Missailidis, PhD Dr Daniel Missailidis is a postdoctoral research fellow and molecular biologist at La Trobe University in Melbourne, Australia. Daniel has researched ME since 2016 and completed his PhD in 2021, having published 11 research papers on ME or Long COVID to date.